

Unleash Immunity

Corporate Presentation *August 2021*

Disclaimers and Forward-Looking Statements

This presentation and the accompanying oral presentation contain forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding possible or assumed future results of operations of TScan Therapeutics, Inc. (the "Company", "we", "our" and "us"), expenses and financing needs, business strategies and plans, research and development plans or expectations, the structure, timing and success of the Company's planned preclinical development and clinical trials, expected milestones, market sizing, competitive position, regulatory matters, industry environment and potential growth opportunities, among other things. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "target," "design," "estimate," "predict," "potential," "plan" or similar expressions or the negative of those terms. The Company has based these forward-looking statements largely on its current expectations and assumptions and on information available as of the date of this presentation. The information in this presentation is provided only as of July 22, 2021 and the Company assumes no obligation to update any forward-looking statements after the date of this presentation, except as required by law.

The forward-looking statements contained in this presentation and the accompanying oral presentation are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results or outcomes to be materially different from any future results or outcomes expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and other factors include, but are not limited to, including the development, clinical and regulatory plans or expectations for the Company's TCR-T therapy candidates, as well as the risks described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's Final Prospectus for its initial public offering, which is on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov. Additional factors may be described in those sections of the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, expected to be filed with the SEC in the third quarter of 2021. You should not put undue reliance on any forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved, if at all. It is not possible for the Company to predict all risks, nor can the Company assess the impact of all factors on its business or the markets in which it operates or the extent to which any factor, or combination of factors, may cause actual results or outcomes to differ materially from those contained in any forward-looking statements the Company may make.



TScan highlights

Proprietary Target and TCR Discovery Platforms

- Enables 'multiplexed' TCR-T therapy

Robust Pipeline in Cancer

- Liquid tumor program 2 INDs, Q4 2021
- Solid tumor program 3 INDs, H2 2022; 1 IND, 2023

Non-Viral Cell Manufacturing

- Enables 'enhanced' T cell engineering

Strategic Partnerships

- Novel oncology target partnership with Novartis

Strong Investor Support

- \$260M from RA Capital, Blackrock, Novartis and others



Our team



David Southwell CEO





Gavin MacBeath, Ph.D. CSO





Brian Silver, JD CFO

FREELINE **P**/**W**/**P** Morgan Stanley



Bill Desmarais, Ph.D. CBO

Momenta Lilly



MGH

Shane Maltbie VP, Finance

Xaxcella porexel. **Deloitte**.



Kite

REGENERON

Shri Chattopadhyay MD; VP, Medical VP, Discovery

Dana-Farber





Cagan Gurer, Ph.D. Warren Jaworowicz VP, CMC

Shire



Jim Murray VP, Clinical Ops



Ken Olivier, Ph.D. VP, Non-clin. Dev.





Ann Hargraves

VP of HR




Sarah Bertino, Ph.D. Director, Corporate Development








Learning from patients who are winning their fight against cancer...






...to treat patients who are not





Multiplexed TCR-T may overcome tumor heterogeneity





Proprietary TCR-T pipeline addresses liquid and solid tumors

	Target	Indications	Discovery	Lead Optimization	IND- Enabling	Phase 1	Phase 2/3
PROPRIETARY PROGRAMS							
Liquid Tumor Program							
TSC-100	HA-1	AML, MDS, ALL ²					
TSC-101	HA-2						
Solid Tumor Program							
TSC-200 ¹	HPV16	Head & Neck, Cervical, Anal, NSCLC ³ , Melanoma					
TSC-201	Target-201						
TSC-202	Target-202						
TSC-203	PRAME						


Note: The TSC-200 product series is designed to be used in combination as part of a multiplexed TCR-T therapy, with treatment tailored to target expression in each patient tumor

¹ TSC-200 will only be developed in HPV-positive cancers, which include head & neck, cervical, and anal cancers

² AML: Acute myeloid leukemia; MDS: Myelodysplastic syndromes; ALL: Acute lymphocytic leukemia



Broad pipeline drives multiple value-creating milestones



TScan Anticipated Milestone Timeline

Liquid Tumor Program Solid Tumor Program


TScan Technology



TScan positioned to overcome solid tumor challenges using multiplexed TCR-T therapy

Most solid tumor patients do not respond to current therapies

Checkpoint / TIL therapy response limited to subset of patients CAR-T efficacy limited to liquid tumors



TCR-T provides a potential solution for solid tumors but is limited by available targets


TScan's platforms overcome current challenges with multiplexed TCR-T

TCR-T can address majority of patients TCR-T can infiltrate solid tumors

TScan platforms enable discovery of novel targets for multiplexed TCR-T




TScan's proprietary platform – TargetScan – enables identification of the natural targets of clinically-active TCRs



Physiologically relevant – natural processing of antigens

Comprehensive – covers every protein in the human proteome


Proprietary library enables discovery of diverse TCR-T targets





TargetScan clearly identifies the targets of TCRs


Genome-wide screen of a TCR known to recognize MAGE-A3






TargetScan identifies clinically relevant off-targets

Genome-wide screen of affinity-enhanced MAGE-A3 TCR





Leveraging TargetScan and ReceptorScan platforms to build a bank of therapeutic TCRs




Discovery of novel TCRs for validated targets

Discovery of **novel TCR/Target pairs** from immunotherapy responders



Novel TCR content and innovative manufacturing platform






Clinical Programs: *Liquid Tumor Program*



Lead program designed to prevent relapse following stem cell transplant (SCT)






Liquid tumor program is designed to meet a high unmet need



malignancies are ineligible for CAR-T therapy **Relapsing patients experience high mortality** – vast majority will die within 1 year TScan uniquely positioned to target prevention of relapse – competitor focus on treating relapse



Liquid tumor program addresses a large and growing market



Number of Allogeneic HCTs in Key TSC-100

HCT use has been increasing ~7% year

over year for the treatment of priority hematologic malignancies (e.g., AML, MDS, ALL)

HCT use is anticipated to continue to grow, driven by:


- Novel pipeline agents improving remission rates prior to transplant, increasing HCT eligibility
- More safe and tolerable conditioning therapies increasing willingness to transplant more patients (e.g., lower risk, elderly)

The TSC-100 program is designed to address a *large, growing pool of addressable patients* in key indications

The TSC-100 program represents a meaningful commercial opportunity that addresses a key unmet need in oncology

~40% of patients receiving HCT will be eligible for TSC-100 and TSC-101


~40% TSC-100/101 eligible



~7K total HCT patients (2018, U.S.)

- ~7K+ patients currently receive HCT for key indications annually in the U.S. alone, with historical growth projected to continue
- Within the HCT pool, ~40% of patients will be eligible for the TSC-100 program based upon HLA type and minor antigen mismatch

Pricing analogs support a premium priced cell therapy asset for relapse prevention






*Calculated as a risk adjusted cost of relapse (i.e., \$450K x 40-50% of patients = \$180-\$220K risk adjusted cost of relapse) Source: CIBMTR; Majhail. Bone Marrow Transplant. 2013; Barrett. Expert Rev Hematol. 2010; Pandya. Avd Ther. 2019; Rautenberg. Int J Mol Sci. 2019; Bejanyan. Biol Blood Marrow Transplant. 2016.

TScan Therapeutics, Inc. 22


Engineering donor T cells to eliminate residual leukemia cells, preventing patient relapse and risk of death





TSC-100 displays strong HA-1-specific cytotoxicity in vitro

Example Cytotoxicity Data




TSC-100 exhibits robust activity via cytotoxicity assays, cytokine production (e.g., IFNg, granzyme B), and T cell proliferation





Illustrative video of *in vitro* studies showing the potential of TSC-100 to reduce HA-1-positive cancer cells

Non engineered T cells



TSC-100








TSC-100 shows enhanced potential safety based on TargetScan safety screen


Off-target TargetScan Safety Data



- TargetScan revealed **no significant off-targets** for the TSC-100 TCR
- TSC-100 demonstrated no cross-reactivity or alloreactivity




Multi-target program provides comprehensive solution for patients following SCT



Clinical Programs: Solid Tumor Program



Solid tumor program targets HPV+ and HPV- tumors




ImmunoBank



Initial targets are expressed in overlapping cancer indications, enabling multiplexed TCR-T therapy


Head & Neck 66 K Incident Patients in U.S. 100% 50% 25% 25% 25% 25% 50% 25% 25% 50% 75% 90% 100 TSC-200 TSC-201 TSC-202 TSC-203

Cervical




Melanoma 100 K Incident Patients in U.S. 100% 95% 90% 50% 50% 0% 50% 0% 0% 50% 50% 50% 0% 50% 50% 50% 0% 50% 50% 50% 0% 50% 50% 50% 0% 50% 50%

NSCLC




TargetScan identifies targets of clinically-active TCRs from immunotherapy-responsive patients






TIL therapy-responsive patients provide another valuable source of clinically-active TCRs




Three Novel Cancer/Testis Antigen Targets Identified from TIL-Responsive Patients






Target-201 is a cancer/testis antigen expressed in various cancers but not healthy tissue




Target-201 TCR kills melanoma cells that naturally express Target-201 in preclinical studies






Discovery process is yielding a diverse and growing Immunobank of TCR-T candidates





ImmunoBank of TCRs may provide customized, off-the-shelf, multiplexed TCR-T



Multiplexed TCR-T may overcome both tumor heterogeneity and resistance due to target loss




Manufacturing



Non-viral delivery overcomes constraints of lentivirus -Enables TCR-T multiplexing and T cell enhancements

T-Integrate Delivery System



Advantages of T-Integrate over lentivirus:

Greater cargo size enables delivery of T cell functional enhancements



Rapid process development



Cost-effective manufacturing




Internal manufacturing expected to facilitate progress to clinic

- 7,000 square foot GMP production facility with QC labs and GMP warehouse
 - Internal manufacturing team with extensive cell therapy experience
- Expected to **fully support multiple clinical programs** through phase 2 clinical trials



Building Corporate Value Through Partnerships






Strategic Novartis partnership builds value in oncology

Partnership with Novartis leveraging TargetScan to discover novel shared targets in solid tumors

- Identifying novel targets and TCRs from patients actively responding to immunotherapy in a select solid tumor indication
- Novartis has the option to license and develop TCRs for up to three novel targets and rights of first negotiation for certain additional TCRs. TScan keeps all additional targets/TCRs not licensed by Novartis
- Payments to TScan include:
 - \$20M upfront plus up to \$10M in research reimbursement
 - Development and commercial milestones
 - Tiered royalties






TargetScan identified COVID-19 T cell targets – Developing next generation vaccines, diagnostics with partners

Using blood from recovering COVID-19 patients, TargetScan found:

- A shared set of targets largely located **outside the spike protein**
- Little cross-reactivity with other 'common cold' coronaviruses
- Results published in Immunity in October 2020

TScan has signed *diagnostic and therapeutic partnerships* as well as early-stage collaborations for COVID-19







Summary



Proprietary target discovery technology identifies novel targets for TCR-T therapy and de-risks development of clinical candidates



TCR-T company with liquid tumor program (IND expected in 2021) and solid tumor program (IND expected in 2022)



Building additional corporate value via strategic partnerships, including recent target discovery partnership with Novartis



Supported by top investors, with \$260M in equity funding

